Is it beneficial to the state to provide insulin-treated diabetic patients with public funds for self-monitoring blood glucose?

Background. In Russia, the prevalence of diabetes continues to increase with the growing diabetes epidemic. In recent years, the paradigm of diabetes treatment has been changing, with patients increasingly becoming equal participants in the treatment process, through the introduction of self-monitoring blood glucose (SMBG). Several clinical studies have demonstrated a positive relationship between SMBG and the decline of the epidemiological and economic burden of diabetes. At present, the procurement of public funds for SMBG is below the specified level in Russia.

Aims. To investigate the potential macroeconomic benefits of public health resource allocation and the use of planned state investments to fund SMBG in insulin-treated diabetic patients.

Materials and methods. This study was conducted with data from insulin-treated diabetic patients. The epidemiological burden of this cohort was determined by the following indicators: the number of patients and the incidence of complications resulting from diabetes, disability, mortality, age and sex. The economic benefits were evaluated by the implementation of two measures: (1) procurement of public funds for the purchase of means for SMBG in patients with insulin-treated diabetes and (2) the use of highly accurate blood glucose metres. To evaluate economic burden, the epidemiological burden was translated into monetary terms using cost-of-illness. Economic benefits were defined as reductions in economic burden.

Results. The economic benefits of public-funded blood glucose test strips for insulin-treated diabetic patients exceeded the required additional investments for their purchase by 1.5 fold. A significant reduction in the inaccuracy of blood glucose metres from 20% to 10% may reduce the economic burden by 9.36 billion RUB. The combined state benefits from the implementation of both measures would significantly decrease the economic burden of diabetes to 29.2 billion RUB.

Conclusions. Increased procurement of public funds for SMBG in insulin-treated diabetic patients would bring economic benefits that far exceed the required investments.

the burden of diabetes, self-control, economic benefits

1. Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet.380(9859):2197-2223. doi: 10.1016/S0140-6736(12)61689-4

2. Дедов И.И. Инновационные технологии в лечении и профилактике сахарного диабета и его осложнений // Сахарный диабет. – 2013. – Т. 16. – №3. – C. 4-10. [Dedov II. Novel technologies for the treatment and prevention of diabetes mellitus and its complications. Diabetes mellitus. 2013;16(3):4-10. (in Russ)]. doi: 10.14341/2072-0351-811

3. Заболеваемость всего населения России в 2014 году. Статистические материалы. ФГБУ «Центральный научно-исследовательский институт организации и информатизации здравоохранения» Минздрава. Москва; 2015 [Zabolevaemost' vsego naseleniya Rossii v 2014 godu. Statisticheskie materialy. FGBU «Tsentral'nyy nauchno-issledovatel'skiy institut organizatsii i informatizatsii zdravookhraneniya» Minzdrava. Moscow; 2015 (in Russ)].

4. Данные Государственного регистра сахарного диабета в РФ за 2014 г. [Dannye Gosudarstvennogo registra sakharnogo diabeta v RF za 2014 g (in Russ)].

5. Государственный доклад о реализации государственной политики в сфере здоровья за 2014 год. Министерство здравоохранения Российской Федерации. Москва; 2014. [Gosudarstvennyy doklad o realizatsii gosudarstvennoy politiki v sfere zdorov'ya za 2014 god. Ministerstvo zdravookhraneniya Rossiyskoy Federatsii. Moscow; 2014 (in Russ)].

6. Dying Too Young. Europe and Central Asia, Human Development Department; 2005. Available from: http://siteresources.worldbank.org/INTECA/Resources/Dying_too_Young_Summary_UPDATED_Oct_19.pdf

7. Заболеваемость всего населения России в 2014 году. Статистические материалы. ФГБУ «Центральный научно-исследовательский институт организации и информатизации здравоохранения» Минздрава. Москва; 2015 [Zabolevaemost' vsego naseleniya Rossii v 2014 godu. Statisticheskie materialy. FGBU «Tsentral'nyy nauchno-issledovatel'skiy institut organizatsii i informatizatsii zdravookhraneniya» Minzdrava. Moscow; 2015 (in Russ)].

8. Дедов И.И., Шестакова М.В., Сунцов Ю.И., и др. Результаты реализации подпрограммы "Сахарный диабет" Федеральной целевой программы "Предупреждение и борьба с социально значимыми заболеваниями 2007–2012 годы" // Сахарный диабет. – 2013. – Т. 16. – №2S. – C. 1-48. [Dedov II, Shestakova MV, Suntsov YI, Peterkova VA, Galstyan GR, Mayorov AY, et al. Federal targeted programme 'Prevention and Management of Socially Significant Diseases (2007-2012)': results of the 'Diabetes mellitus' sub-programme. Diabetes mellitus. 2013;16(2S):1-48 (in Russ)] doi: 10.14341/2072-0351-3879

9. Guide to Identifying the Economic Consequences of Disease and Injury, World Health Organization 2009, Appendix B Critical overview of the cost of illness methodology. Available from: http://www.who.int/choice/publications/d_economic_impact_guide.pdf

10. Дедов И.И., Шестакова М.В., Галстян Г.Р., и др. Алгоритмы специализированной медицинской помощи больным сахарнымдиабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск) // Сахарный диабет. – 2015. – Т. 18. – №1S – C. 1-112. [Dedov II, Shestakova MV, Galstyan GR, et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition). Diabetes mellitus. 2015;18(1S):1-112.] doi: 10.14341/DM20151S1-112

11. Ziegler R, Heidtmann B, Hilgard D, et al. Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2011;12(1):11-17. doi: 10.1111/j.1399-5448.2010.00650.x

12. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.

13. Czupryniak L, Barkai L, Bolgarska S, et al. Self-monitoring of blood glucose in diabetes: from evidence to clinical reality in Central and Eastern Europe--recommendations from the international Central-Eastern European expert group. Diabetes Technol Ther. 2014;16(7):460-475. doi: 10.1089/dia.2013.0302

14. Schnell O, Erbach M, Wintergerst E. Higher accuracy of self-monitoring of blood glucose in insulin-treated patients in Germany: clinical and economical aspects. J Diabetes Sci Technol. 2013;7(4):904-912. doi: 10.1177/193229681300700413

15. Schnell O, Erbach M. Impact of a reduced error range of SMBG in insulin-treated patients in Germany. J Diabetes Sci Technol. 2014;8(3):479-482. doi: 10.1177/1932296813516206

16. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.

17. Czupryniak L, Barkai L, Bolgarska S, et al. Self-Monitoring of Blood Glucose in Diabetes: From Evidence to Clinical Reality in Central and Eastern Europe—Recommendations from the International Central-Eastern European Expert Group. Diabetes Technology & Therapeutics. 2014;16(7):460-475. doi: 10.1089/dia.2013.0302

18. Barceló A, Aedo C, Rajpathak S, Robles S. The cost of diabetes in Latin America and the Caribbean. Bulletin of the World Health Organization. 2003;81(1):19-27.

19. Ray JA, Valentine WJ, Secnik K, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin. 2005;21(10):1617-1629. doi: 10.1185/030079905X65349